Brief: Revance Provides Corporate Update At Investor Day

Revance Therapeutics

19/09/2023 14:13

Sept 19 (Reuters) - Revance Therapeutics Inc  RVNC.O :
    * REVANCE PROVIDES CORPORATE UPDATE AT INVESTOR DAY
    * REVANCE THERAPEUTICS INC: Q3 2023 PRODUCT REVENUE HAS
POTENTIAL
TO BE AROUND Q2 2023 LEVELS
    * REVANCE THERAPEUTICS INC: 2023 OUTLOOK GAAP OPERATING
EXPENSES
UPDATED FROM $460 MILLION - $480 MILLION TO $545 MILLION - $585
MILLION.
    * REVANCE THERAPEUTICS INC: 2023 OUTLOOK NON-GAAP RESEARCH
AND
DEVELOPMENT EXPENSES UPDATED FROM $80 MILLION - $90 MILLION TO
$75 MILLION - $85 MILLION

Source text for Eikon:  ID:nBw4yjvgya 
Further company coverage:  RVNC.O 

 ((Reuters.Briefs@thomsonreuters.com))